175 related articles for article (PubMed ID: 37208431)
1. Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia.
Korczowski B; Farrell C; Falone M; Blackman N; Rodgers T
Pediatr Res; 2023 Oct; 94(4):1547-1554. PubMed ID: 37208431
[TBL] [Abstract][Full Text] [Related]
2. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA;
Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-deficiency Anemia.
Ding Y; Zhu X; Li X; Zhang H; Wu M; Liu J; Palmen M; Roubert B; Li C
Clin Ther; 2020 Feb; 42(2):276-285. PubMed ID: 31937462
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases.
Laass MW; Straub S; Chainey S; Virgin G; Cushway T
BMC Gastroenterol; 2014 Oct; 14():184. PubMed ID: 25326048
[TBL] [Abstract][Full Text] [Related]
7. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
8. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
Lichtenstein GR; Onken JE
Dig Dis Sci; 2018 Nov; 63(11):3009-3019. PubMed ID: 30056562
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
[TBL] [Abstract][Full Text] [Related]
10. Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review.
Aksan A; Zepp F; Anand S; Stein J
Eur J Pediatr; 2022 Nov; 181(11):3781-3793. PubMed ID: 36056175
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study.
Ikuta K; Ito H; Takahashi K; Masaki S; Terauchi M; Suzuki Y
Int J Hematol; 2019 Jan; 109(1):50-58. PubMed ID: 30194568
[TBL] [Abstract][Full Text] [Related]
12. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia.
Ikuta K; Shimura A; Terauchi M; Yoshii K; Kawabata Y
Int J Hematol; 2018 May; 107(5):519-527. PubMed ID: 29357079
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
Howaldt S; Domènech E; Martinez N; Schmidt C; Bokemeyer B
Inflamm Bowel Dis; 2022 Mar; 28(3):373-384. PubMed ID: 33988236
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
[TBL] [Abstract][Full Text] [Related]
16. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis.
Shin HW; Go DY; Lee SW; Choi YJ; Ko EJ; You HS; Jang YK
Medicine (Baltimore); 2021 May; 100(20):e24571. PubMed ID: 34011020
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Bailie GR; Mason NA; Valaoras TG
Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949
[TBL] [Abstract][Full Text] [Related]
20. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]